Jan 28 (Reuters) - Johnson & Johnson JNJ.N :
* HEALTH CANADA APPROVES NEW INDICATION FOR INVOKANA®* (CANAGLIFLOZIN) TO REDUCE RISKS ASSOCIATED WITH DIABETIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES
* JANSSEN - NEW INDICATION IS BASED ON RESULTS FROM PHASE 3 CREDENCE STUDY